The firm, which was set up to move Huntingdon Life Sciences’ financial centre to the US, delisted from the New York Stock Exchange on November 25 after shareholders approved Lion’s $8.50 per share buyout.
Like many preclinical contract research organisations (CRO), LSR has had a difficult 2009 with progressive quarterly reports dominated by falling revenues and operating income.